On the role of unmutated antigens in tumor rejection in mice with unperturbed T-cell repertoires

Cancer Research

Volumn 63, Issue 18, 2003, Pages 6051-6055

  Sarma, Supria ^a,b   Bai, Xue Feng ^a   Liu, Jin Qing ^a   May Jr , Kenneth F ^a   Zheng, Pan ^a   Liu, Yang ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b 129 Hamilton Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

P1A ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSFECTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; THYMUS; TUMOR REJECTION; WILD TYPE;

ANIMALS; ANTIGENS, NEOPLASM; EPITOPES, T-LYMPHOCYTE; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TRANSFECTION;

EID: 0141842626     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Prehn, R. T., and Main, J. M. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. (Bethesda), 18: 769-778, 1957.
2. Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E., and Boom, T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med., 173: 1373-1384, 1991.
3. Monach, P. A., Meredith, S. C., Siegel, C. T., and Schreiber, H. A unique tumor antigen produced by a single amino acid substitution. Immunity, 2: 45-59, 1995.
4. Dubey, P., Hendrickson, R. C., Meredith, S. C., Siegel, C. T., Shabanowitz, J., Skipper, J. C., Engelhard, V. H., Hunt, D. F., and Schreiber, H. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med., 185: 695-705, 1997.
5. Wang, Y. C., Zhu, L., McHugh, R., Graham, S. D., Jr., Hillyer, C. D., Dillehay, D., Sell, K. W., and Selvaraj, P. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD80) costimulation. J. Immunother. Emphasis Tumor Immunol., 19: 1-8, 1996.
6. Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Buschenfelde, K. H., and Beach, D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Wash. DC), 269: 1281-1284, 1995.
7. Wolfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Buschenfelde, K. H., and Boon, T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol., 24: 759-764, 1994.
8. Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
9. Boon, T., De Plaen, E., Lurquin, C., Van den Eynde, B., van der Bruggen, P., Traversari, C., Amar-Costesec, A., and Van Pel, A. Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surv., 13: 23-37, 1992.
10. Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D., and Schreiber, H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA, 96: 8633-8638, 1999.
11. Brandle, D., Bilsborough, J., Rulicke, T., Uyttenhove, C., Boon, T., and Van den Eynde, B. J. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol., 28: 4010-4019, 1998.
12. Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., and Restifo, N. P. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"- reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med., 188: 277-286, 1998.
13. McCabe, B. J., Irvine, K. R., Nishimura, M. I., Yang, J. C., Spiess, P. J., Shulman, E. P., Rosenberg, S. A., and Restifo, N. P. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res., 55: 1741-1747, 1995.
14. Brandle, D., Brasseur, F., Weynants, P., Boon, T., and Van den Eynde, B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med., 183: 2501-2508, 1996.
15. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
16. Zeh, H. J., III, Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A., and Yang, J. C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol., 162: 989-994, 1999.
17. Yang, G., Hellstrom, K. E., Mizuno, M. T., and Chen, L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J. Immunol., 155: 3897-3903, 1995.
18. Bai, X. F., Liu, J., Li, O., Zheng, P., and Liu, Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J. Clin. Investig., III: 1487-1496, 2003.
19. Lehmann, P. V., Forsthuber, T., Miller, A., and Sercarz, E. E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature (Lond.), 358: 155-157, 1992.
20. Bai, X. F., Bender, J., Liu, J., Zhang, H., Wang, Y., Li, O., Du, P., Zheng, P., and Liu, Y. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J. Immunol., 167: 3936-3943, 2001.
21. + T lymphocytes in vivo. J. Exp. Med., 194: 1339-1348, 2001.
22. Liu, X., Gao, J-X., Wen, J., Yin, J., Li, O., Zuo, T., Gajewski, T. F., Fu, Y-X., Zheng, P., and Liu, L. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J. Exp. Med., 197: 1721-1730, 2003.
23. Ramarathinam, L., Sarma, S., Maric, M., Zhao, M., Yang, G., Chen, L., and Liu, Y. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol., 155: 5323-5329, 1995.
24. Sarma, S., Guo, Y., Guilloux, Y., Lee, C., Bai, X-F., and Liu, Y. Cytotoxic T lymphocytes to an unmutated tumor antigen P1A: normal development but restrained effector function. J. Exp. Med., 189: 811-820, 1999.
25. Ramarathinam, L., Castle, M., Wu, Y., and Liu, Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med., 179: 1205-1214, 1994.
26. Maric, M., Zheng, P., Sarma, S., Guo, Y., and Liu, Y. Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells. Cancer Res., 58: 3376-3384, 1998.
27. Gao, J-X., Zhang, H., Bai, X. F., Wen, J., Zheng, X., Liu, J., Zheng, P., and Liu, Y. Peripheral blockade of B7-1 and B7-2 inhibits clonal deletion of highly pathogenic autoreactive T cells. J. Exp. Med., 195: 959-971, 2002.
28. Zheng, P., Guo, Y., Niu, Q., Levy, D. E., Dyck, J. A., Lu, S., Sheiman, L. A., and Liu, Y. Proto-oncogene PML controls genes devoted to MHC class 1 antigen presentation. Nature (Lond.), 396: 373-376, 1998.
29. Zheng, P., Sarma, S., Guo, Y., and Liu, Y. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res., 59: 3461-3467, 1999.
30. Wortzel, R. D., Philipps, C., and Schreiber, H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature (Lond.), 304: 165-167, 1983.
31. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., and Davis, M. M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-685, 1999.
32. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J. L., Lienard, D., Cerottini, J. C., and Cerundolo, V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med., 188: 1641-1650, 1998.
33. Irvine, K. R., McCabe, B. J., Rosenberg, S. A., and Restifo, N. P. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J. Immunol., 154: 4651-4657, 1995.
34. Uyttenhove, C., Godfraind, C., Lethe, B., Amar-Costesec, A., Renauld, J. C., Gajewski, T. F., Duffour, M. T., Warnier, G., Boon, T., and Van den Eynde, B. J. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int. J. Cancer, 70: 349-356, 1997.
35. Derbinski, J., Schulte, A., Kyewski, B., and Klein, L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol., 2: 1032-1039, 2001.